Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARVN
ARVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARVN News
Arvinas Hosts Fourth Annual Impact Day for Community Service
May 18 2026
Newsfilter
Arvinas Q1 2026 Earnings Call Insights
May 12 2026
seekingalpha
Rigel Partners with Arvinas and Pfizer for Breast Cancer Treatment
May 12 2026
stocktwits
Arvinas Reports Q1 Earnings Miss with Significant Revenue Decline
May 12 2026
seekingalpha
Major Companies Reporting Earnings Next Week
May 03 2026
CNBC
Arvinas and Pfizer Launch VEPPANU for Breast Cancer
May 02 2026
NASDAQ.COM
FDA Approves Pfizer and Arvinas Breast Cancer Drug
May 01 2026
Newsfilter
FDA Approves First PROTAC Therapy for Breast Cancer
May 01 2026
stocktwits
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era
May 01 2026
Newsfilter
FDA Approves Breast Cancer Therapy Developed by Pfizer and Arvinas
May 01 2026
seekingalpha
ARVINAS INC AND PFIZER TO CHOOSE THIRD-PARTY PARTNER FOR VEPPANU COMMERCIALIZATION
May 01 2026
moomoo
ARVINAS INC - FDA APPROVES BEFORE PDUFA DATE OF JUNE 5, 2026
May 01 2026
moomoo
ARVINAS RECEIVES FDA APPROVAL FOR VEPPANU (VEPDEGESTRANT) TO TREAT ESR1M, ER+/HER2- ADVANCED BREAST CANCER
May 01 2026
moomoo
FDA GREENLIGHTS VEPDEGESTRANT FOR ADVANCED OR METASTATIC ER-POSITIVE, HER2-NEGATIVE, ESR1-MUTATED BREAST CANCER
May 01 2026
moomoo
Arvinas Shares Surge 6.9% on Positive Pipeline Expectations
Apr 02 2026
NASDAQ.COM
Insider Buying by Waters and Arvinas Directors
Mar 11 2026
NASDAQ.COM
Show More News
